Uterine cancer easily curable with immunotherapy.

Malignant change of the endometrial lining of the uterine cavity causes uterine cancer. This cancer is the most common gynecologic cancers. Over 35000 women are diagnosed each year across the world (Most women diagnosed with uterine cancer have their menopause, while only 5% of cases are diagnosed in women under 40 years old). The incidence is on a slow rise secondary to the obesity epidemic. The most common subtype is endometrioid adenocarcinoma. This cancer is the most frequent occurring in the female genital tract. Immunotherapy can be helpful.

Until, the cause endometrial cancer is not known exactly. But there are some factors that were identified that might increase or decrease the risk of developing this cancer. Many of the risk factors for uterine cancer relate to the body’s exposure to the female sex hormone such as estrogen or to the balance between types of the two female sex hormones that are estrogen and progesterone. Estrogen without progesterone to balance it increases the risk of this cancer. This cancer is much more common in women after the menopause as the body stops making progesterone, but they are still produces a small amount of estrogen. 

Several risk factors are identified for this cancer that involve age, obesity, diabetes and high blood, infertility and nulliparity, menstrual history, endometrial hyperplasia, polycystic ovary syndrome (PCOS), family history, drugs (Tamoxifen and Raloxifene), chemicals (Talcum powder), diet, and physical activity. 

The most common symptom of uterine cancer is abnormal vaginal bleeding after menopause. Post menopausal bleeding, which is a key symptom of womb cancer in most cases. Vaginal discharge from pink and watery to dark and foul smelling. Only a small number of women with dysfunctional uterine bleeding will actually have womb cancer. Less common symptoms of womb cancer can include lower abdominal  pain or discomfort, and dysparonia.

Immunotherapy based immunotherapeutic cancer agents play an important role in the treatment of uterine cancer. Bevacizumab (Monoclonal antibody drug), Sunitinib, Sorafenib, VEGF-Trap,Trabectedin, Temsirolimus, and much more immunotherapeutic cancer agents are running in the various phases (phase 0, phase 1, phase2, and phase 3) of the clinical trials for evaluation of kind of study for Food and Drug Administration (FDA) approval for the treatment of uterine cancer.

Global Allied Pharmaceuticals (GAP) has a team of experts for immunotherapy and immune combination therapy. GAP has services for cancer patients. Our experts are providing all suitable services and treatments to cancer patients on the basis of their disease stage.

Further more information about us, kindly visit at www.gapsos.com